Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Quantum BioPharma Ltd C.QNTM

Alternate Symbol(s):  QNTM

Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), it is focused on... see more

CSE:QNTM - Post Discussion

Quantum BioPharma Ltd > FSD Delisting?
View:
Post by GrahamB on Oct 10, 2021 9:39pm

FSD Delisting?

Really interesting article over an equity guru, that summarizes nicely the horrible failure, missed opportunities, executive miss management

Here are a few choice quotes:


Is FSD Pharma (HUGE.N) getting into psychedelics to avoid being kicked off the Nasdaq?

 

 “

The company filed an Investigational IND with the FDA in August 2020 and was given the green light just a month later to initiate a phase 2 clinical trial for the use of FSD201 to treat COVID-19. But last month announced they were terminating the study. Another L for FSD Pharma. Can we please change this company’s name to SMDH Pharma. They were cannabis, then they were Covid, now they are psychedelics. They can’t seem to make up their mind, it all feels pretty random and fly by night.”

 

They also seem to burn their bridges after each phase instead of integrating a series of different verticals under one rooftop kind of like Revive (RVV.C) did. It’s been a bizarre strategy and the company’s share price has been nothing more than a flatline with the occasional blip for years now. Whatever trend comes after psychedelics I wouldn’t surprised to see another pivot, CEO, rollback, etc”

 

“FSD Pharma announced back in August it was acquiring 100% of the issued and outstanding shares Lucid Psycheceuticals Inc. (“Lucid”), a Canadian-based specialty psychedelic pharmaceutical company focused on the development of therapies to treat critical neurodegenerative diseases, for roughly $11.3 million CAD in FSD Pharma stock. Prof. Lakshmi Kotra, co-founder and CEO of Lucid, commented, “We started with a vision to accelerate therapies for Total Brain Health.” My counter to that would be, you just took $11.3 million CAD in FSD shares “

 

https://equity.guru/2021/09/20/no-one-is-excited-about-fsd-pharma-huge-n-getting-into-psychedelics/

Comment by CristinaVentura on Oct 11, 2021 7:58pm
Bet on a company like FSD and the proposals of psychedelics in response to neurological treatments? It may be revolutionary, let's continue to see what happens.
Comment by Mil_Man54 on Oct 11, 2021 8:04pm
Look at that....new account and the very first post is to pump FSD.......look beyond the PR hype and dig into FSD and the BoD/Management to see what they have done and why they're in the state they're in. as well as whi is responsible......ignore these pumpers and do your own DD.......
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities